Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

HIGHLIGHTS

• who: Martin Bergman from the Analysis Group, Inc, Boston, MA, USA have published the research: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial, in the Journal: (JOURNAL) of March/22,/2017
• what: Data on the primary and ranked secondary outcomes of this study have been published previously . Not all PROs assessed in this study have known normative values, thus achievement of normative values is only reported for a subset of PROs . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.